Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024
Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024
– Simultaneously Published by the Journal of Clinical Oncology –
— 由《臨床腫瘤學雜誌》同時出版 —
Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also published simultaneously in the Journal of Clinical Oncology. The company previously announced that the study did not meet the primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
吉利德科學公司（納斯達克股票代碼：GILD）今天公佈了三期 EVOKE-01 研究的詳細結果，該結果將在今天（美國中部時間下午 2:45-5:45）的2024年美國臨床腫瘤學會（ASCO）年會上口頭會議（摘要 #LBA8500）中公佈。結果還同時發表在 臨床腫瘤學雜誌。該公司此前宣佈，該研究未達到先前接受過治療的轉移性非小細胞肺癌（NSCLC）的總存活率（OS）的主要終點。
譯文內容由第三人軟體翻譯。